Search

Karl J. Puttlitz

Examiner (ID: 12924, Phone: (571)272-0645 , Office: P/1671 )

Most Active Art Unit
1621
Art Unit(s)
1671, 1621, 1204, 1646, 1642
Total Applications
2355
Issued Applications
1616
Pending Applications
153
Abandoned Applications
628

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 18492279 [patent_doc_number] => 11697690 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-11 [patent_title] => Site-specific glycoengineering of targeting moieties [patent_app_type] => utility [patent_app_number] => 17/215674 [patent_app_country] => US [patent_app_date] => 2021-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 82 [patent_figures_cnt] => 114 [patent_no_of_words] => 34432 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17215674 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/215674
Site-specific glycoengineering of targeting moieties Mar 28, 2021 Issued
Array ( [id] => 17213172 [patent_doc_number] => 20210346508 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/210081 [patent_app_country] => US [patent_app_date] => 2021-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34706 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17210081 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/210081
Anti-HER2 biparatopic antibody-drug conjugates and methods of use Mar 22, 2021 Issued
Array ( [id] => 18619193 [patent_doc_number] => 11752215 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-12 [patent_title] => Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties [patent_app_type] => utility [patent_app_number] => 17/200136 [patent_app_country] => US [patent_app_date] => 2021-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 28 [patent_no_of_words] => 14371 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 283 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17200136 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/200136
Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties Mar 11, 2021 Issued
Array ( [id] => 18994617 [patent_doc_number] => 11911434 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-27 [patent_title] => Stable antibody-drug conjugate, preparation method therefor, and use thereof [patent_app_type] => utility [patent_app_number] => 17/180412 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 76 [patent_no_of_words] => 13076 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180412 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/180412
Stable antibody-drug conjugate, preparation method therefor, and use thereof Feb 18, 2021 Issued
Array ( [id] => 16899013 [patent_doc_number] => 20210177929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => NEW STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/180645 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180645 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/180645
Stable antibody-drug conjugate, preparation method therefor, and use thereof Feb 18, 2021 Issued
Array ( [id] => 16900635 [patent_doc_number] => 20210179551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => PROCESS FOR PRODUCING ALKALI TAURINATE [patent_app_type] => utility [patent_app_number] => 17/176326 [patent_app_country] => US [patent_app_date] => 2021-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6114 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17176326 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/176326
PROCESS FOR PRODUCING ALKALI TAURINATE Feb 15, 2021 Abandoned
Array ( [id] => 18575524 [patent_doc_number] => 11732038 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-22 [patent_title] => Conjugates comprising cell-binding agents and cytotoxic agents [patent_app_type] => utility [patent_app_number] => 17/174911 [patent_app_country] => US [patent_app_date] => 2021-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 45 [patent_no_of_words] => 42492 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 169 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17174911 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/174911
Conjugates comprising cell-binding agents and cytotoxic agents Feb 11, 2021 Issued
Array ( [id] => 18978794 [patent_doc_number] => 11903948 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-20 [patent_title] => Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof [patent_app_type] => utility [patent_app_number] => 17/169087 [patent_app_country] => US [patent_app_date] => 2021-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 11392 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 288 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17169087 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/169087
Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof Feb 4, 2021 Issued
Array ( [id] => 18257059 [patent_doc_number] => 20230084099 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => ANTI-MEFLIN ANTIBODY FOR USE IN TREATMENT OF CANCER IN SUBJECT HAVING CANCER, AND PHARMACEUTICAL COMPOSITION COMPRISING THE ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/759952 [patent_app_country] => US [patent_app_date] => 2021-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17997 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759952 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/759952
ANTI-MEFLIN ANTIBODY FOR USE IN TREATMENT OF CANCER IN SUBJECT HAVING CANCER, AND PHARMACEUTICAL COMPOSITION COMPRISING THE ANTIBODY Feb 2, 2021 Pending
Array ( [id] => 17035203 [patent_doc_number] => 20210252161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/166713 [patent_app_country] => US [patent_app_date] => 2021-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17166713 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/166713
Site specific homogeneous with KSP inhibitors Feb 2, 2021 Issued
Array ( [id] => 17052236 [patent_doc_number] => 20210261670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => NOVEL ANTI-BMPR1B ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/163246 [patent_app_country] => US [patent_app_date] => 2021-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17163246 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/163246
NOVEL ANTI-BMPR1B ANTIBODIES AND METHODS OF USE Jan 28, 2021 Abandoned
Array ( [id] => 18186338 [patent_doc_number] => 11576896 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-14 [patent_title] => Benzoselenophene-based compounds, pharmaceutical compositions and antibody-drug conjugates including the same [patent_app_type] => utility [patent_app_number] => 17/161771 [patent_app_country] => US [patent_app_date] => 2021-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 7338 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17161771 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/161771
Benzoselenophene-based compounds, pharmaceutical compositions and antibody-drug conjugates including the same Jan 28, 2021 Issued
Array ( [id] => 18183607 [patent_doc_number] => 20230044337 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => VACCINATION AGAINST ANTIGENS INDUCED IN PATHOGEN-INFECTED CELLS [patent_app_type] => utility [patent_app_number] => 17/759139 [patent_app_country] => US [patent_app_date] => 2021-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9292 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759139 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/759139
VACCINATION AGAINST ANTIGENS INDUCED IN PATHOGEN-INFECTED CELLS Jan 27, 2021 Pending
Array ( [id] => 18283677 [patent_doc_number] => 20230099149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/796707 [patent_app_country] => US [patent_app_date] => 2021-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33187 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17796707 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/796707
Treatment of cancer Jan 27, 2021 Issued
Array ( [id] => 18620641 [patent_doc_number] => 11753669 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-12 [patent_title] => Lysine conjugated immunoglobulins [patent_app_type] => utility [patent_app_number] => 17/159655 [patent_app_country] => US [patent_app_date] => 2021-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 12 [patent_no_of_words] => 33269 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 313 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17159655 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/159655
Lysine conjugated immunoglobulins Jan 26, 2021 Issued
Array ( [id] => 18619192 [patent_doc_number] => 11752214 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-12 [patent_title] => Protein-antiviral compound conjugates [patent_app_type] => utility [patent_app_number] => 17/156525 [patent_app_country] => US [patent_app_date] => 2021-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 34909 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17156525 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/156525
Protein-antiviral compound conjugates Jan 22, 2021 Issued
Array ( [id] => 18286263 [patent_doc_number] => 20230101735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => ANTI-TROP-2 ANTIDODY-EXATECAN ANALOG CONJUGATE AND MEDICAL USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/793005 [patent_app_country] => US [patent_app_date] => 2021-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20383 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793005 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/793005
ANTI-TROP-2 ANTIDODY-EXATECAN ANALOG CONJUGATE AND MEDICAL USE THEREOF Jan 21, 2021 Pending
Array ( [id] => 18284350 [patent_doc_number] => 20230099822 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION [patent_app_type] => utility [patent_app_number] => 17/793419 [patent_app_country] => US [patent_app_date] => 2021-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793419 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/793419
MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION Jan 17, 2021 Abandoned
Array ( [id] => 20254863 [patent_doc_number] => 12427196 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Macromolecular prodrugs for light-emitting diodes and uses thereof [patent_app_type] => utility [patent_app_number] => 17/793276 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 29 [patent_no_of_words] => 28524 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793276 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/793276
Macromolecular prodrugs for light-emitting diodes and uses thereof Jan 14, 2021 Issued
Array ( [id] => 18700117 [patent_doc_number] => 11786605 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => Site specific antibody-drug conjugates with peptide-containing linkers [patent_app_type] => utility [patent_app_number] => 17/144378 [patent_app_country] => US [patent_app_date] => 2021-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 47385 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17144378 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/144378
Site specific antibody-drug conjugates with peptide-containing linkers Jan 7, 2021 Issued
Menu